Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 4:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: dexpramipexole Clear all
Terminated Phase 3 Interventional

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.

NCT05763121
View directory record Official record
Conditions
Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
Interventions
Dexpramipexole Dihydrochloride, Placebo
Drug
Lead sponsor
Areteia Therapeutics
Industry
Eligibility
12 Years to 99 Years
Enrollment
1,061 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
89
States / cities
Bakersfield, California • La Palma, California • Newport Beach, California + 73 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 21, 2026, 4:37 PM EDT
Completed Phase 2 Interventional

Bipolar Study of Seroquel XR With Pramipexole Dihydrochloride

NCT00893841
View directory record Official record
Conditions
Bipolar Depression
Interventions
quetiapine (Seroquel) XR, placebo, pramipexole dihydrochloride
Drug
Lead sponsor
Dr. D McIntosh & Dr. K Kjernisted Clinical Research Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
San Diego, California • Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced Sep 21, 2026, 4:37 PM EDT
Completed Phase 1Phase 2 Interventional

Pramipexole and Morphine for Renal Colic

NCT04160520
View directory record Official record
Conditions
Renal Colic
Interventions
Pramipexole, Morphine, Placebo oral tablet
Drug
Lead sponsor
East Carolina University
Other
Eligibility
19 Years to 66 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Sep 21, 2026, 4:37 PM EDT
Completed Phase 4 Interventional Results available

Naltrexone for Impulse Control Disorders in Parkinson's Disease

NCT01052831
View directory record Official record
Conditions
Impulse Control Disorder, Parkinson Disease
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 5, 2015 · Synced Sep 21, 2026, 4:37 PM EDT
Completed Early Phase 1 Interventional Results available

Non-Opioid Pramipexole and Pain

NCT03842709
View directory record Official record
Conditions
Chronic Pain
Interventions
Pramipexole Oral Tablet, Placebo
Drug · Other
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Sep 21, 2026, 4:37 PM EDT
Completed Phase 1 Interventional

Effects of a Dopamine Agonist on Pharmacodynamics of Levodopa in Parkinson's Disease

NCT00666653
View directory record Official record
Conditions
Parkinson's Disease
Interventions
pramipexole
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
30 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 24, 2008 · Synced Sep 21, 2026, 4:37 PM EDT
Completed Phase 4 Interventional Results available

Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients

NCT00144300
View directory record Official record
Conditions
Parkinson Disease
Interventions
Mirapex, Requip
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
30 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
21
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Fountain Valley, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2014 · Synced Sep 21, 2026, 4:37 PM EDT
Completed Phase 3 Interventional Results available

Pramipexole Conversion to Ropinirole Controlled Release (CR)

NCT00275275
View directory record Official record
Conditions
Parkinson Disease
Interventions
Requip PR, Mirapex
Drug
Lead sponsor
Rajesh Pahwa, MD
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Sep 21, 2026, 4:37 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Gait Analysis in Neurological Disease

NCT02994719
View directory record Official record
Conditions
Parkinson's Disease, Parkinsonian Disorders, Atypical Parkinson Disease, Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration, Gait, Frontal, Huntington Disease, Ataxia, Spinocerebellar
Interventions
Anti-Parkinson medication, Deep Brain Stimulation
Drug · Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 21, 2026, 4:37 PM EDT
Completed Phase 3 Interventional Results available

Polysomnography Study Of Pregabalin And Pramipexole Versus Placebo In Patients With Restless Legs Syndrome And Associated Sleep Disturbance

NCT00991276
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
pregabalin, placebo, pramipexole
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
41
States / cities
Jasper, Alabama • Phoenix, Arizona • Tucson, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2021 · Synced Sep 21, 2026, 4:37 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD

NCT06533553
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Dexpramipexole Dihydrochloride
Drug
Lead sponsor
Areteia Therapeutics
Industry
Eligibility
40 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
23
States / cities
Conway, Arkansas • Newport Beach, California • Northridge, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Sep 21, 2026, 4:37 PM EDT
Recruiting Phase 2 Interventional

Stratified Pharmacological Approaches for Regulating Circuit-Level Effects

NCT07022405
View directory record Official record
Conditions
Depression - Major Depressive Disorder
Interventions
Pramipexole Immediate Release
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 21, 2026, 4:37 PM EDT
Enrolling by invitation Phase 4 Interventional

Quality Improvement and Practice Based Research in Neurology Using the EMR

NCT02670161
View directory record Official record
Conditions
Brain Tumors, Epilepsy, Migraine, Mild Cognitive Impairment, Concussion, Multiple Sclerosis, Neuropathy, Parkinson's, Restless Legs Syndrome, Stroke
Interventions
Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 100 Years
Enrollment
3,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 23, 2025 · Synced Sep 21, 2026, 4:37 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Imaging the Nucleus Accumbens in Major Depressed Patients 'Treated With Pramipexole

NCT01066897
View directory record Official record
Conditions
Depression
Interventions
Pramipexole
Drug
Lead sponsor
Stanford University
Other
Eligibility
20 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Sep 21, 2026, 4:37 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Treatment of Restless Legs Symptoms With Pramipexole to Improve the Outcomes of Protracted Opioid Withdrawal in OUD

NCT04759703
View directory record Official record
Conditions
Sleep Disorder, Restless Legs Syndrome, Opioid-use Disorder, Opioid Withdrawal
Interventions
Pramipexole, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts • Quincy, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 21, 2026, 4:37 PM EDT
Active, not recruiting Phase 4 Interventional

Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy

NCT05003648
View directory record Official record
Conditions
Adrenoleukodystrophy, Restless Legs Syndrome
Interventions
Pramipexole, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 21, 2026, 4:37 PM EDT
Completed Phase 4 Interventional Results available

Targeting Cognition in Bipolar Disorder With Pramipexole

NCT02397837
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Pramipexole, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts • Glen Oaks, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Sep 21, 2026, 4:37 PM EDT
Completed Phase 4 Interventional

SWITCH:Restless Legs Patients Switched to Ropinirole From Pramipexole

NCT00344994
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
pramipexole
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated May 12, 2011 · Synced Sep 21, 2026, 4:37 PM EDT
Completed Phase 4 Interventional Results available

A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease

NCT01711866
View directory record Official record
Conditions
Advanced Idiopathic Parkinson's Disease
Interventions
Rotigotine
Drug
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
30 Years to 80 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Anniston, Alabama • Atlantis, Florida • Miami Springs, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2014 · Synced Sep 21, 2026, 4:37 PM EDT
Terminated No phase listed Observational

The Long Term Impact of Initiating Pramipexole Versus Levodopa in Early Parkinson's Disease (CALM-PD Cohort Study)

NCT00804479
View directory record Official record
Conditions
Parkinson's Disease
Interventions
No intervention.
Other
Lead sponsor
University of Rochester
Other
Eligibility
Not listed
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Sep 21, 2026, 4:37 PM EDT
Completed Phase 4 Interventional Results available

Switching From Oral Dopamine Agonists to Rotigotine

NCT01976871
View directory record Official record
Conditions
Restless Legs Syndrome, Ekbom Syndrome, Willis-Ekbom Disease
Interventions
Rotigotine
Drug
Lead sponsor
John Winkelman, MD, PhD
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Sep 21, 2026, 4:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dexpramipexole and Warfarin Drug Drug Interaction (DDI) Study

NCT01597310
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Warfarin, Dexpramipexole
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Sep 21, 2026, 4:37 PM EDT
Completed Phase 1 Interventional

Pramipexole as a Treatment for Cocaine Dependence

NCT01651377
View directory record Official record
Conditions
Cocaine Addiction, Cocaine Abuse, Cocaine Dependence, Substance Abuse
Interventions
Pramipexole, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Sep 21, 2026, 4:37 PM EDT
Not listed Phase 2 Interventional

A Study to Evaluate in Patients With Parkinsonian Type Disorders

NCT03683225
View directory record Official record
Conditions
Idiopathic Parkinson Disease
Interventions
CTC-413
Combination Product
Lead sponsor
Chase Therapeutics Corporation
Industry
Eligibility
40 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Farmington Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Sep 21, 2026, 4:37 PM EDT